Serial administration of rhBMP-2 and alendronate enhances the differentiation of osteoblasts
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sang-Hyon | - |
dc.contributor.author | Choi, Hye-Jung | - |
dc.contributor.author | Yoon, Dae Sung | - |
dc.contributor.author | Son, Chang-Nam | - |
dc.date.accessioned | 2022-02-17T15:40:17Z | - |
dc.date.available | 2022-02-17T15:40:17Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 1756-1841 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136115 | - |
dc.description.abstract | Aim The incorporation of growth factors is an effective strategy to accelerate bone induction. Bone morphogenetic protein-2 (BMP-2) promotes osteoblast differentiation and induces bone formation. Alendronate (ALN) is an osteoclast deactivation drug. We investigated the effect of serial administration of recombinant human BMP-2 (rhBMP-2) and ALN on osteoblast differentiation. Methods The effect of serial administration of rhBMP-2 (0-150 ng/mL) and ALN (0-15 mu mol/L) on the viability and differentiation of a clonal murine calvarial cell line, MC3T3-E1, was evaluated at various concentrations and for different periods. The Cell Counting Kit-8 assay was used to assess cell viability. The alkaline phosphatase activity was evaluated as an indicator of osteogenic differentiation. The expression levels of runt domain-containing transcription factor 2 (Runx2) and osteopontin (OPN) were analyzed by real-time polymerase chain reaction and western blotting. Statistical analyses were performed using Student's t test. Results The serial treatment with rhBMP-2 and ALN increased the expression of the differentiation-related factors Runx2 and OPN, as well as the differentiation ability of osteoblasts compared with individual or simultaneous treatment. The osteoblasts treated with rhBMP-2 followed by ALN showed the highest differentiation. The degree of differentiation in the group treated with rhBMP-2 for 7 days followed by ALN for 3 days was increased by 1.5 times compared with that of the group treated with rhBMP-2 alone (P < .01). Conclusion These findings indicate that the serial administration of rhBMP-2 and ALN may exert osteogenic effects on osteoblastic cells via the upregulation of Runx2 and OPN. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | BONE | - |
dc.subject | BMP-2 | - |
dc.title | Serial administration of rhBMP-2 and alendronate enhances the differentiation of osteoblasts | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Dae Sung | - |
dc.identifier.doi | 10.1111/1756-185X.14189 | - |
dc.identifier.scopusid | 2-s2.0-85111485908 | - |
dc.identifier.wosid | 000678644800001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, v.24, no.10, pp.1266 - 1272 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | - |
dc.citation.volume | 24 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1266 | - |
dc.citation.endPage | 1272 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | BMP-2 | - |
dc.subject.keywordPlus | BONE | - |
dc.subject.keywordAuthor | alendronate | - |
dc.subject.keywordAuthor | bone morphogenetic protein-2 | - |
dc.subject.keywordAuthor | osteogenesis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.